The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Japan OKs Omicron COVID-19 Vaccines from Pfizer, Moderna
The Japanese health ministry on September 12 approved two Omicron-adapted bivalent mRNA vaccines for COVID-19 developed respectively by Pfizer and Moderna, with an eye towards their rollout this month. The two vaccines - “Comirnaty RTU intramuscular injection (Bivalent: Original/Omicron BA.1)”…
To read the full story
Related Article
- Japan to Roll Out BA.4/5 Omicron Boosters on Oct. 13, Inoculations for 6 Months to 4 Years from Oct. 24
October 11, 2022
- MHLW Panel to Discuss Shortening of COVID Booster Interval
October 11, 2022
- Pfizer’s BA.4/5-Adapted Comirnaty Grabs Special Approval in Japan
October 6, 2022
- Pfizer Seeks Japan Nod for BA.4/5-Adapted COVID-19 Vaccine
September 13, 2022
- Pfizer/Moderna’s Omicron Vaccines on Japan Panel Agenda on Sept. 12
September 8, 2022
- Japan Govt to Start Omicron Vaccine Distribution from Week of Sept. 19
September 6, 2022
- PM Kishida Vows Earlier Rollout of Omicron Boosters
September 1, 2022
- Moderna Files Omicron Bivalent Vaccine in Japan
August 10, 2022
- Japan to Begin BA.1-Based Omicron Booster Program as Early as October
August 9, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
- MHLW Eyes Omicron-Specific Jabs for All Residents Given Primary Inoculations
July 26, 2022
- Omicron-Specific Boosters to Be Introduced This Fall or Later: Panel
July 25, 2022
REGULATORY
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
- MHLW Drafts Guideline Update, Urges Makers to Factor Distribution Costs into WPPs
December 16, 2025
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
- MHLW Council Determines 3 “Drug Loss” Products as High-Need, to Seek Development
December 16, 2025
- LDP Biosimilar Group Submits Request to Finance Minister, Seeks Continued Support
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…